Clinical trials: Sirolimus, completed
Diabetes Mellitus, Type 1
Pre Transplant Rapamycin Treatment in Islet Transplantation Alone
Numerous changes to the original Edmonton protocol have been proposed in the attempt of improving the still unsatisfactory long-term function of ITA.
- Trial name
- ITA-Rp (NCT01060605)
- Testing
- rapamycin
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- IRCCS San Raffaele
Kidney Transplant
The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.
The study is being done to compare the safety and effects (good and bad) of three different combinations of immunosuppression drugs used by kidney transplant recipients while also looking at their kidney function.
- Trial name
- NCT00275522
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Renal Transplantation
Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients
Chronic transplant nephropathy and cardiovascular death are the main reasons for loss of transplanted organs after kidney transplantation.
- Trial name
- NCT00204321
- Testing
- sirolimus (drug), mmf (drug)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Muenster
Coronary Artery Disease
Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry (SECURE)
The objective of this study is to allow treatment with the sirolimus-eluting Bx VELOCITYTM stent in patients with a serious disease or condition for which there is no generally acceptable alternate treatment available.
- Trial name
- NCT00231244
- Testing
- CYPHER Sirolimus-Eluting Coronary Stent
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
A Study of Diabetic Patients With De Novo Native Coronary Artery Lesions
The main objective of this study is to assess the safety and effectiveness of the CYPHER sirolimus-eluting stent in maintaining minimum lumen diameter in de novo native coronary artery lesions as compared to the uncoated Bx…
- Trial name
- SCORPIUS (NCT00495898)
- Testing
- CYPHER sirolimus-eluting stent, uncoated Bx VELOCITY balloon-expandable stent
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
The main objective of this study is to assess the safety and effectiveness of the sirolimus-eluting Bx VELOCITYTM stent in reducing in-lesion late loss in patients with de novo native coronary artery lesions.
- Trial name
- NCT00232752
- Testing
- 4.0 CYPHER Sirolimus-Eluting Coronary Stent
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cordis US Corp.
In-Stent Restenosis
Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)
The main objective of this study is to demonstrate the superiority or non-inferiority of the sirolimus-eluting Bx VELOCITY® stent compared to intravascular brachytherapy in patients with in-stent restenotic native coronary artery…
- Trial name
- NCT00231257
- Testing
- Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent, Brachytherapy
- Where
- United States
- Volunteers
- 384 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Double or Single Dose Sirolimus-Eluting Stents in Diabetic Patients With de Novo Coronary Artery Lesions
The main objective of this study is to assess safety and effectiveness of double dose sirolimus-eluting Bx VELOCITY stents in diabetic patients with a de novo native coronary lesion, as compared to single dose sirolimus-eluting…
- Trial name
- 3D (NCT00233714)
- Testing
- CYPHER Sirolimus-Eluting Coronary Stent
- Where
- Brazil
- Volunteers
- 56 people
- Sponsor
- Cordis US Corp.
Coronary Stenosis
The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R.)
1500 eligible patients will be treated with the commercially available CYPHER® sirolimus-eluting Bx Velocity™ stent. Patients will be followed to twelve months post-procedure, watching for patients that require a repeat procedure…
- Trial name
- NCT00403338
- Testing
- CYPHER® Bx Velocity™ stent (sirolimus-eluting)
- Volunteers
- 1,500 people
- Sponsor
- Cordis US Corp.
Advanced Solid Tumor, Refractory to Standard Therapies
Phase 1 Study With Sorafenib and Sirolimus
The purpose of the trial is to identify the recommended dose of sorafenib and sirolimus for combination therapy in subsequent phase 2 trials.
- Trial name
- NCT00509613
- Testing
- Sorafenib, Sirolimus
- Where
- Netherlands
- Sponsor
- Radboud University Medical Center
Coronary Artery Disease
Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)
The main objective of this study is to assess the safety and effectiveness of the sirolimus-coated Bx VELOCITYTM stent in reducing target vessel failure in de novo native coronary artery lesions as compared to the uncoated Bx…
- Trial name
- NCT00232765
- Testing
- CYPHER Sirolimus-Eluting Stent, Uncoated BX VELOCITY Balloon-Expandable Stent
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Cordis US Corp.
Graft vs Host Disease, Kidney Transplantation
Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
To evaluate the safety of long-term administration of sirolimus oral solution for up to 5 additional years, or until the tablet formulation is commercially available (whichever occurs first) in solid organ transplant recipients…
- Trial name
- NCT00037531
- Testing
- Sirolimus (RAPAMUNE)
- Where
- 20 sites in United States, Canada
- Volunteers
- 769 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Chronic Kidney Failure, Graft vs Host Disease
Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
The incidence of efficacy failure at 12 months between two regimens.
- Conditions
- Chronic Kidney Failure, Graft vs Host Disease, Kidney Transplantation
- Trial name
- NCT00044720
- Testing
- Rapamune
- Volunteers
- 484 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Coronary Artery Disease
Intra-Individual Comparison of Sirolimus and Paclitaxel Coated Stent (FRE-RACE Study)
The main objective of this study is to assess the safety and effectiveness of the Sirolimus eluting Cypher Select(TM) stent in reducing angiographic in-stent late loss in de novo native coronary lesions as compared to the…
- Trial name
- NCT00130546
- Testing
- Paclitaxel-eluting TAXUS(TM), Sirolimus eluting Cypher Select(TM)
- Where
- Germany
- Volunteers
- 112 people
- Sponsor
- University Hospital Freiburg
Coronary Artery Disease
The Study of the BX VELOCITY Stent In Patients With De Novo Coronary Artery Lesions.
The main objective of this study is to assess the safety and effectiveness of the sirolimus-coated Bx VELOCITY™ stent in maintaining minimum lumen diameter in de novo native coronary artery lesions as compared to the uncoated Bx…
- Trial name
- E-SIRIUS (NCT00235144)
- Testing
- sirolimus-coated Bx Velocity stent, uncoated Bx Velocity stent
- Where
- 2 sites in Germany
- Volunteers
- 353 people
- Sponsor
- Cordis US Corp.
Coronary Restenosis
Oral Sirolimus for In-Stent Restenosis
Despite recent advances in interventional cardiology including the success of drug-eluting stents in de-novo coronary lesions, the treatment of in-stent restenosis remains a challenging clinical issue.
- Trial name
- OSIRIS (NCT00859183)
- Testing
- Sirolimus
- Where
- 3 sites in Germany
- Volunteers
- 300 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Angioplasty
Spot Drug-Eluting Stenting for Long Coronary Stenoses
Most doctors who use the new drug-eluting stents for the treatment of long coronary narrowings tend to cover the full length of the lesion with long or multiple stents.
- Trial name
- NCT00738556
- Testing
- Drug-eluting stents (Cypher and Taxus)
- Where
- 2 sites in Greece
- Volunteers
- 179 people
- Sponsor
- Cardiovascular Research Society, Greece
Kidney Transplantation, Chronic Kidney Disease
Calcineurin Free Immunosuppression in Renal Transplant Recipients
The main purpose of this study is to obtain preliminary information on the efficacy, safety and cost of two regimens, Rapamycin / MMF / steroid therapy and Cyclosporine A Neoral / MMF / steroid therapy, used in the prevention of…
- Trial name
- NCT00812123
- Testing
- Sirolimus, Cyclosporine A, Prednisone
- Where
- Switzerland
- Volunteers
- 127 people
- Sponsor
- University Hospital, Basel, Switzerland
Coronary Artery Disease
The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.
The main objective of this study is to assess the safety and effectiveness of the sirolimus coated Bx VELOCITY stent in reducing angiographic in-stent late loss in de novo native coronary lesions as compared to the bare metal Bx…
- Trial name
- RAVEL (NCT00233805)
- Testing
- Sirolimus coated Bx Velocity™, Bare metal Bx Velocity™
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Cordis US Corp.
Renal Artery Stenosis
A Comparison of Coated and Uncoated Stents in Renal Artery Treatment.
The primary objective of this study is to compare the safety and performance of the Palmaz Genesis™ balloon expandable stent, with or without sirolimus coating in the treatment of renal artery stenosis, measured at 6 months…
- Trial name
- GREAT (NCT00235157)
- Testing
- Sirolimus-eluting Palmaz Genesis peripheral stent
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 105 people
- Sponsor
- Cordis US Corp.